文献速递心律失常高血压血脂与心血管预防

老年人群房颤筛查:一项随机临床试验

Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该多中心随机临床试验纳入≥75岁、有高血压且无已知房颤的患者856例,比较可穿戴连续心电贴片筛查与常规护理。家庭血压计间歇筛查敏感性仅35.0%,劣于连续心电监测。

要点

  • 可穿戴连续心电贴片筛查使老年高血压患者房颤检出率提高约10倍。
  • 连续心电检出房颤者中75.0%启动抗凝治疗。
  • 家庭血压计间歇筛查敏感性35.0%,不推荐作为首选筛查工具。

核心结论

  • 在≥75岁社区高血压人群中,可穿戴连续心电监测筛查房颤耐受性好,使房颤检出率提高约10倍,并促使多数检出者启动抗凝治疗。
  • 与连续心电相比,家庭血压计间歇示波筛查阵发性房颤敏感性低,为劣效策略。
  • 尚需硬终点大型试验评估房颤筛查的获益与危害。

研究设计与样本

  • 多中心随机临床试验,2015年4月5日至2019年3月26日从48家初级保健机构招募≥75岁、有高血压且无已知房颤的参与者856例。
  • 筛查组接受基线和3个月时各2周连续心电贴片监测,并在此期间每日两次使用具有示波法房颤筛查功能的自动家庭血压计;对照组接受标准护理。
  • 主要结局为6个月内经连续心电监测或临床发现的房颤,采用意向筛查分析。

主要发现

  • 连续心电检出房颤者中,房颤总时间中位数6.3小时(IQR 4.2-14.0小时,范围1.3小时-28天),最长单次发作中位数5.7小时(IQR 2.9-12.9小时)。
  • 家庭血压计每日两次房颤筛查敏感性35.0%(95%CI 15.4%-59.2%),特异性81.0%(95%CI 76.7%-84.8%),阳性预测值8.9%(95%CI 4.9%-15.5%),阴性预测值95.9%(95%CI 94.5%-97.0%)。
  • 连续心电监测因皮肤不良反应提前终止者5/434例(1.2%)。

临床怎么用

  • 对≥75岁合并高血压的社区人群,可考虑使用可穿戴连续心电贴片进行房颤筛查以提高检出率。
  • 连续心电检出房颤后应评估抗凝指征,多数患者可启动抗凝治疗以预防卒中。
  • 家庭血压计间歇示波筛查敏感性低,不宜作为房颤筛查的替代策略。

局限性

  • 研究未报告硬临床终点(如卒中、出血),筛查的净获益尚不明确。
  • 样本来自初级保健机构,结果外推需谨慎。
  • 连续心电监测依从性中位佩戴27.4/28天,但皮肤不良反应导致1.2%提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atrial fibrillation (AF) is a major cause of preventable strokes. Screening asymptomatic individuals for AF may increase anticoagulant use for stroke prevention. OBJECTIVE: To evaluate 2 home-based AF screening interventions. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial recruited individuals from primary care practices aged 75 years or older with hypertension and without known AF. From April 5, 2015, to March 26, 2019, 856 participants were enrolled from 48 practices. INTERVENTIONS: The control group received standard care (routine clinical follow-up plus a pulse check and heart auscultation at baseline and 6 months). The screening group received a 2-week continuous electrocardiographic (cECG) patch monitor to wear at baseline and at 3 months, in addition to standard care. The screening group also received automated home blood pressure (BP) machines with oscillometric AF screening capability to use twice-daily during the cECG monitoring periods. MAIN OUTCOMES AND MEASURES: With intention-to-screen analysis, the primary outcome was AF detected by cECG monitoring or clinically within 6 months. Secondary outcomes included anticoagulant use, device adherence, and AF detection by BP monitors. RESULTS: Of the 856 participants, 487 were women (56.9%); mean (SD) age was 80.0 (4.0) years. Median cECG wear time was 27.4 of 28 days (interquartile range [IQR], 18.4-28.0 days). In the primary analysis, AF was detected in 23 of 434 participants (5.3%) in the screening group vs 2 of 422 (0.5%) in the control group (relative risk, 11.2; 95% CI, 2.7-47.1; P = .001; absolute difference, 4.8%; 95% CI, 2.6%-7.0%; P < .001; number needed to screen, 21). Of those with cECG-detected AF, median total time spent in AF was 6.3 hours (IQR, 4.2-14.0 hours; range 1.3 hours-28 days), and median duration of the longest AF episode was 5.7 hours (IQR, 2.9-12.9 hours). Anticoagulation was initiated in 15 of 20 patients (75.0%) with cECG-detected AF. By 6 months, anticoagulant therapy had been prescribed for 18 of 434 participants (4.1%) in the screening group vs 4 of 422 (0.9%) in the control group (relative risk, 4.4; 95% CI, 1.5-12.8; P = .007; absolute difference, 3.2%; 95% CI, 1.1%-5.3%; P = .003). Twice-daily AF screening using the home BP monitor had a sensitivity of 35.0% (95% CI, 15.4%-59.2%), specificity of 81.0% (95% CI, 76.7%-84.8%), positive predictive value of 8.9% (95% CI, 4.9%-15.5%), and negative predictive value of 95.9% (95% CI, 94.5%-97.0%). Adverse skin reactions requiring premature discontinuation of cECG monitoring occurred in 5 of 434 participants (1.2%). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, among older community-dwelling individuals with hypertension, AF screening with a wearable cECG monitor was well tolerated, increased AF detection 10-fold, and prompted initiation of anticoagulant therapy in most cases. Compared with continuous ECG, intermittent oscillometric screening with a BP monitor was an inferior strategy for detecting paroxysmal AF. Large trials with hard clinical outcomes are now needed to evaluate the potential benefits and harms of AF screening. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02392754.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 33625468. doi:10.1001/jamacardio.2021.0038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。